We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App





US ‘Operation Warp Speed’ To Ready 300 Million Vaccine Doses by End Of 2020

By HospiMedica International staff writers
Posted on 01 May 2020
The Trump administration is reportedly bringing biotech, pharma and federal agencies together in a project dubbed “Operation Warp Speed” that aims to cut the COVID-19 vaccine’s development time and deliver 100 million doses in the US by the end of the year.

The World Health Organization estimates more than 100 coronavirus vaccine candidates to be currently in development. More...
Experts do not expect a vaccine to be ready for at least 12 to 18 months. Under project “Operation Warp Speed”, pharmaceutical companies, government agencies and the military will work together to cut that time by up to eight months. The administration will help biopharma companies coordinate their individual efforts by providing assistance through federal agencies and the US military. The project is similar to the Manhattan Project-style joint initiative which brought different sectors together to develop the nation’s atomic bomb.

The officials are looking at a master trial protocol that would allow researchers to simultaneously study different vaccines instead of studying each vaccine separately through independent studies by pharmaceutical companies. The administration plans to speed up distribution by scaling up manufacturing capabilities as the vaccines enter large human trials. The goal of project “Operation Warp Speed” is to have 300 million doses of vaccine available by January.

In a media interview, Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases and a key member of the White House Coronavirus Task Force, said that developing a vaccine to combat the coronavirus outbreak by January was “doable.” Dr. Fauci said that it was possible to ready hundreds of millions of doses of a coronavirus vaccine by January. However, meeting the January deadline will ultimately depend upon whether the results of trials prove that the vaccine works.

“We're going to start ramping up production with the companies involved and you do that at risk, in other words you don't wait until you get an answer before you start manufacturing, you at risk, proactively, start making it, assuming it's going to work,” said Dr. Fauci. “And if it does, then you can scale up and hopefully get to that timeline.”


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
12-Channel ECG
CM1200B
New
Hemostatic Agent
HEMOBLAST Bellows
New
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The tool could help healthcare providers more accurately identify patients who have higher CVD risk (Photo courtesy of 123RF)

New Tool Predicts Cardiovascular Disease Risk More Accurately

Cardiovascular disease (CVD) affects over 127 million adults in the U.S. and remains a leading cause of illness and death. Accurate prediction of CVD risk is essential for guiding early interventions,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.